Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees
Open Access
- 31 July 2025
- journal article
- editorial
- Published by MDPI AG in Microorganisms
- Vol. 13 (8) , 1787
Abstract
In a previous study, eight chronically HBV-infected nucleos (t)ide analog (NA)-naïve patients began receiving entecavir (ETV) concomitant with a single ARC-520 HBV siRNA injection. This single dose of ARC-520 (SD) was followed by 6–8 months of ETV alone before the patients received 4–9 monthly doses of ARC-520, the multi-dose (MD) period, while continuing ETV. Quantities of HBV DNA, RNA, and antigens were measured from serum and a liver biopsy collected ~30 months after the last MD from five patients. All full-length HBV transcripts from the livers were characterized. Viral parameters and HBV transcripts from patients were compared to these measurements collected at multiple points in ARC-520 + ETV-treated chronically HBV-infected chimpanzees. Multiple forms of HBx mRNA were observed, and these differed between chimpanzees and patients. Products of cccDNA were greatly decreased in patients who were previously highly viremic and HBeAg+, although a biopsied patient had similar amounts of cccDNA to the highly viremic HBeAg+ chimpanzees. The comparison of all HBV transcripts and cccDNA levels between patients and chimpanzees demonstrate the transcriptional silencing of cccDNA following the siRNA treatment of patients but not the chimpanzees that received a different treatment regimen. Results from this small study suggest that continued NA treatment during and between periods of HBV antigen re-expression post-siRNA treatment enhanced viral parameter reductions.Keywords
This publication has 43 references indexed in Scilit:
- Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBJournal of Hepatology, 2022
- Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral loadJournal of Hepatology, 2021
- Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serumJournal of Hepatology, 2020
- Hepatitis B virus replicating in hepatocellular carcinoma encodes HBx variants with preserved ability to antagonize restriction by Smc5/6Antiviral Research, 2019
- Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis BJournal of Hepatology, 2017
- Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy VolunteersClinical Pharmacology in Drug Development, 2016
- Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different PotencyClinical Gastroenterology and Hepatology, 2013
- Hepatitis B virus X protein is essential to initiate and maintain virus replication after infectionJournal of Hepatology, 2011
- Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patientsHepatology, 2004
- Leaky transcription termination produces larger and smaller than genome size hepatitis B virus X gene transcriptsVirology, 1991